Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?

Background Different hypotheses have been proposed about the future development of morbidity associated with the temporal improvement in life expectancy. However, many studies have focused on general morbidity while testing these hypotheses. In type 2 diabetes (T2D), one of the most prevalent chroni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of public health 2021-10, Vol.31 (Supplement_3)
Hauptverfasser: Safieddine, B, Sperlich, S, Epping, J, Lange, K, Geyer, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_3
container_start_page
container_title European journal of public health
container_volume 31
creator Safieddine, B
Sperlich, S
Epping, J
Lange, K
Geyer, S
description Background Different hypotheses have been proposed about the future development of morbidity associated with the temporal improvement in life expectancy. However, many studies have focused on general morbidity while testing these hypotheses. In type 2 diabetes (T2D), one of the most prevalent chronic diseases, research points towards an increasing prevalence over time with a simultaneous increase in life expectancy among this population. While morbidity compression in T2D can thus be ruled out, it remains unclear whether morbidity expansion or dynamic equilibrium applies, which could be the case with a decrease in personal disease burden despite increasing prevalence. Against this background, this study aims to examine how the prevalence of T2D-related comorbidities is developing over time. Methods Using claims data of a large statutory insurance provider in the state of Lower-Saxony, Germany, the period prevalence of nine T2D-related comorbidities was examined for the time periods 2005-2007, 2010-2012, and 2015-2017 in 240241, 295868, and 308134 individuals with T2D, respectively. The temporal development of comorbidities was examined by logistic regression analysis. The change in the number of comorbidities over time was examined by ordered logistic regression. Analyses were stratified by gender and three age groups. Results Over the three time periods, age-adjusted predicted probabilities for more severe cardiovascular diseases (CVDs) decreased in men and women with T2D while those for less severe CVDs and other vascular diseases such as retinopathy, polyneuropathy any nephropathy increased significantly in all subgroups. Among all subgroups, the predicted probability of having more comorbidities over time also increased significantly. Conclusions Despite differences in the way CVDs are developing, the results are in favour of the morbidity expansion hypothesis for this population. Further research is needed to examine the reasons behind the observed trends. Key messages The developement of comorbidities in individuals with type 2 diabetes points towards morbidity expansion among this population. Future studies should examine whether the change is socioeconomic status, medication use and lifestyle risk factors are contributing to these trends.
doi_str_mv 10.1093/eurpub/ckab164.332
format Article
fullrecord <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_proquest_journals_2597251631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurpub/ckab164.332</oup_id><sourcerecordid>2597251631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1532-cda9f098daf6c71e4b5f882c46019265809e3936da0d80602bf176abd4b312933</originalsourceid><addsrcrecordid>eNqNkF1LwzAUhoMoOKd_wKuA13U5SZs23ohs8wMm3kzwQghJm0Lm2nRJI_bfW-l-gFfnhfO858CD0DWQWyCCLUz0XdSL8ktp4OktY_QEzSDlacI4-TgdMxBIgHJ6ji5C2BFCsrygM_S5Mt9m77rGtD12NV66xnltK9tbE7Bt8XboDKZ4ZZU2vQl3-PW4H_D6p1NtsK7FzuPV0KrGlnh9iHZvtbexub9EZ7XaB3N1nHP0_rjeLp-TzdvTy_Jhk5SQMZqUlRI1EUWlal7mYFKd1UVBy5QTEJRnBRGGCcYrRaqCcEJ1DTlXuko1AyoYm6Ob6W7n3SGa0Mudi74dX0qaiZxmwBmMFJ2o0rsQvKll522j_CCByD-LcrIojxblaHEsJVPJxe4__C87pncw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2597251631</pqid></control><display><type>article</type><title>Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?</title><source>Oxford Journals Open Access Collection</source><creator>Safieddine, B ; Sperlich, S ; Epping, J ; Lange, K ; Geyer, S</creator><creatorcontrib>Safieddine, B ; Sperlich, S ; Epping, J ; Lange, K ; Geyer, S</creatorcontrib><description>Background Different hypotheses have been proposed about the future development of morbidity associated with the temporal improvement in life expectancy. However, many studies have focused on general morbidity while testing these hypotheses. In type 2 diabetes (T2D), one of the most prevalent chronic diseases, research points towards an increasing prevalence over time with a simultaneous increase in life expectancy among this population. While morbidity compression in T2D can thus be ruled out, it remains unclear whether morbidity expansion or dynamic equilibrium applies, which could be the case with a decrease in personal disease burden despite increasing prevalence. Against this background, this study aims to examine how the prevalence of T2D-related comorbidities is developing over time. Methods Using claims data of a large statutory insurance provider in the state of Lower-Saxony, Germany, the period prevalence of nine T2D-related comorbidities was examined for the time periods 2005-2007, 2010-2012, and 2015-2017 in 240241, 295868, and 308134 individuals with T2D, respectively. The temporal development of comorbidities was examined by logistic regression analysis. The change in the number of comorbidities over time was examined by ordered logistic regression. Analyses were stratified by gender and three age groups. Results Over the three time periods, age-adjusted predicted probabilities for more severe cardiovascular diseases (CVDs) decreased in men and women with T2D while those for less severe CVDs and other vascular diseases such as retinopathy, polyneuropathy any nephropathy increased significantly in all subgroups. Among all subgroups, the predicted probability of having more comorbidities over time also increased significantly. Conclusions Despite differences in the way CVDs are developing, the results are in favour of the morbidity expansion hypothesis for this population. Further research is needed to examine the reasons behind the observed trends. Key messages The developement of comorbidities in individuals with type 2 diabetes points towards morbidity expansion among this population. Future studies should examine whether the change is socioeconomic status, medication use and lifestyle risk factors are contributing to these trends.</description><identifier>ISSN: 1101-1262</identifier><identifier>EISSN: 1464-360X</identifier><identifier>DOI: 10.1093/eurpub/ckab164.332</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Age groups ; Cardiovascular diseases ; Chronic illnesses ; Comorbidity ; Compression ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Equilibrium ; Hypotheses ; Life expectancy ; Life span ; Men ; Morbidity ; Nephropathy ; Polyneuropathy ; Population studies ; Public health ; Regression analysis ; Retinopathy ; Risk analysis ; Risk factors ; Socioeconomic status ; Socioeconomics ; Statistical analysis ; Subgroups ; Time periods ; Trends ; Vascular diseases</subject><ispartof>European journal of public health, 2021-10, Vol.31 (Supplement_3)</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1604,27866,27924,27925</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/eurpub/ckab164.332$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc></links><search><creatorcontrib>Safieddine, B</creatorcontrib><creatorcontrib>Sperlich, S</creatorcontrib><creatorcontrib>Epping, J</creatorcontrib><creatorcontrib>Lange, K</creatorcontrib><creatorcontrib>Geyer, S</creatorcontrib><title>Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?</title><title>European journal of public health</title><description>Background Different hypotheses have been proposed about the future development of morbidity associated with the temporal improvement in life expectancy. However, many studies have focused on general morbidity while testing these hypotheses. In type 2 diabetes (T2D), one of the most prevalent chronic diseases, research points towards an increasing prevalence over time with a simultaneous increase in life expectancy among this population. While morbidity compression in T2D can thus be ruled out, it remains unclear whether morbidity expansion or dynamic equilibrium applies, which could be the case with a decrease in personal disease burden despite increasing prevalence. Against this background, this study aims to examine how the prevalence of T2D-related comorbidities is developing over time. Methods Using claims data of a large statutory insurance provider in the state of Lower-Saxony, Germany, the period prevalence of nine T2D-related comorbidities was examined for the time periods 2005-2007, 2010-2012, and 2015-2017 in 240241, 295868, and 308134 individuals with T2D, respectively. The temporal development of comorbidities was examined by logistic regression analysis. The change in the number of comorbidities over time was examined by ordered logistic regression. Analyses were stratified by gender and three age groups. Results Over the three time periods, age-adjusted predicted probabilities for more severe cardiovascular diseases (CVDs) decreased in men and women with T2D while those for less severe CVDs and other vascular diseases such as retinopathy, polyneuropathy any nephropathy increased significantly in all subgroups. Among all subgroups, the predicted probability of having more comorbidities over time also increased significantly. Conclusions Despite differences in the way CVDs are developing, the results are in favour of the morbidity expansion hypothesis for this population. Further research is needed to examine the reasons behind the observed trends. Key messages The developement of comorbidities in individuals with type 2 diabetes points towards morbidity expansion among this population. Future studies should examine whether the change is socioeconomic status, medication use and lifestyle risk factors are contributing to these trends.</description><subject>Age groups</subject><subject>Cardiovascular diseases</subject><subject>Chronic illnesses</subject><subject>Comorbidity</subject><subject>Compression</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Equilibrium</subject><subject>Hypotheses</subject><subject>Life expectancy</subject><subject>Life span</subject><subject>Men</subject><subject>Morbidity</subject><subject>Nephropathy</subject><subject>Polyneuropathy</subject><subject>Population studies</subject><subject>Public health</subject><subject>Regression analysis</subject><subject>Retinopathy</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Socioeconomic status</subject><subject>Socioeconomics</subject><subject>Statistical analysis</subject><subject>Subgroups</subject><subject>Time periods</subject><subject>Trends</subject><subject>Vascular diseases</subject><issn>1101-1262</issn><issn>1464-360X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><recordid>eNqNkF1LwzAUhoMoOKd_wKuA13U5SZs23ohs8wMm3kzwQghJm0Lm2nRJI_bfW-l-gFfnhfO858CD0DWQWyCCLUz0XdSL8ktp4OktY_QEzSDlacI4-TgdMxBIgHJ6ji5C2BFCsrygM_S5Mt9m77rGtD12NV66xnltK9tbE7Bt8XboDKZ4ZZU2vQl3-PW4H_D6p1NtsK7FzuPV0KrGlnh9iHZvtbexub9EZ7XaB3N1nHP0_rjeLp-TzdvTy_Jhk5SQMZqUlRI1EUWlal7mYFKd1UVBy5QTEJRnBRGGCcYrRaqCcEJ1DTlXuko1AyoYm6Ob6W7n3SGa0Mudi74dX0qaiZxmwBmMFJ2o0rsQvKll522j_CCByD-LcrIojxblaHEsJVPJxe4__C87pncw</recordid><startdate>20211020</startdate><enddate>20211020</enddate><creator>Safieddine, B</creator><creator>Sperlich, S</creator><creator>Epping, J</creator><creator>Lange, K</creator><creator>Geyer, S</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7TQ</scope><scope>C1K</scope><scope>DHY</scope><scope>DON</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20211020</creationdate><title>Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?</title><author>Safieddine, B ; Sperlich, S ; Epping, J ; Lange, K ; Geyer, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1532-cda9f098daf6c71e4b5f882c46019265809e3936da0d80602bf176abd4b312933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age groups</topic><topic>Cardiovascular diseases</topic><topic>Chronic illnesses</topic><topic>Comorbidity</topic><topic>Compression</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Equilibrium</topic><topic>Hypotheses</topic><topic>Life expectancy</topic><topic>Life span</topic><topic>Men</topic><topic>Morbidity</topic><topic>Nephropathy</topic><topic>Polyneuropathy</topic><topic>Population studies</topic><topic>Public health</topic><topic>Regression analysis</topic><topic>Retinopathy</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Socioeconomic status</topic><topic>Socioeconomics</topic><topic>Statistical analysis</topic><topic>Subgroups</topic><topic>Time periods</topic><topic>Trends</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Safieddine, B</creatorcontrib><creatorcontrib>Sperlich, S</creatorcontrib><creatorcontrib>Epping, J</creatorcontrib><creatorcontrib>Lange, K</creatorcontrib><creatorcontrib>Geyer, S</creatorcontrib><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>European journal of public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Safieddine, B</au><au>Sperlich, S</au><au>Epping, J</au><au>Lange, K</au><au>Geyer, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?</atitle><jtitle>European journal of public health</jtitle><date>2021-10-20</date><risdate>2021</risdate><volume>31</volume><issue>Supplement_3</issue><issn>1101-1262</issn><eissn>1464-360X</eissn><abstract>Background Different hypotheses have been proposed about the future development of morbidity associated with the temporal improvement in life expectancy. However, many studies have focused on general morbidity while testing these hypotheses. In type 2 diabetes (T2D), one of the most prevalent chronic diseases, research points towards an increasing prevalence over time with a simultaneous increase in life expectancy among this population. While morbidity compression in T2D can thus be ruled out, it remains unclear whether morbidity expansion or dynamic equilibrium applies, which could be the case with a decrease in personal disease burden despite increasing prevalence. Against this background, this study aims to examine how the prevalence of T2D-related comorbidities is developing over time. Methods Using claims data of a large statutory insurance provider in the state of Lower-Saxony, Germany, the period prevalence of nine T2D-related comorbidities was examined for the time periods 2005-2007, 2010-2012, and 2015-2017 in 240241, 295868, and 308134 individuals with T2D, respectively. The temporal development of comorbidities was examined by logistic regression analysis. The change in the number of comorbidities over time was examined by ordered logistic regression. Analyses were stratified by gender and three age groups. Results Over the three time periods, age-adjusted predicted probabilities for more severe cardiovascular diseases (CVDs) decreased in men and women with T2D while those for less severe CVDs and other vascular diseases such as retinopathy, polyneuropathy any nephropathy increased significantly in all subgroups. Among all subgroups, the predicted probability of having more comorbidities over time also increased significantly. Conclusions Despite differences in the way CVDs are developing, the results are in favour of the morbidity expansion hypothesis for this population. Further research is needed to examine the reasons behind the observed trends. Key messages The developement of comorbidities in individuals with type 2 diabetes points towards morbidity expansion among this population. Future studies should examine whether the change is socioeconomic status, medication use and lifestyle risk factors are contributing to these trends.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/eurpub/ckab164.332</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1101-1262
ispartof European journal of public health, 2021-10, Vol.31 (Supplement_3)
issn 1101-1262
1464-360X
language eng
recordid cdi_proquest_journals_2597251631
source Oxford Journals Open Access Collection
subjects Age groups
Cardiovascular diseases
Chronic illnesses
Comorbidity
Compression
Diabetes
Diabetes mellitus (non-insulin dependent)
Equilibrium
Hypotheses
Life expectancy
Life span
Men
Morbidity
Nephropathy
Polyneuropathy
Population studies
Public health
Regression analysis
Retinopathy
Risk analysis
Risk factors
Socioeconomic status
Socioeconomics
Statistical analysis
Subgroups
Time periods
Trends
Vascular diseases
title Development of Comorbidities in Type 2 Diabetes: Morbidity Expansion or Dynamic Equilibrium?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A55%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Comorbidities%20in%20Type%202%20Diabetes:%20Morbidity%20Expansion%20or%20Dynamic%20Equilibrium?&rft.jtitle=European%20journal%20of%20public%20health&rft.au=Safieddine,%20B&rft.date=2021-10-20&rft.volume=31&rft.issue=Supplement_3&rft.issn=1101-1262&rft.eissn=1464-360X&rft_id=info:doi/10.1093/eurpub/ckab164.332&rft_dat=%3Cproquest_TOX%3E2597251631%3C/proquest_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2597251631&rft_id=info:pmid/&rft_oup_id=10.1093/eurpub/ckab164.332&rfr_iscdi=true